Orion re-acquires rights to Simdax from Abbott
This article was originally published in Scrip
Executive Summary
Orion, a Finnish pharmaceutical company and diagnostics company, is to pay Abbott $18 million to re-acquire the rights to the intravenous formulation of its heart failure treatment levosimendan, which is marketed as Simdax.